Monday, September 14, 2026
● 2 updates — View →
Latest update · Aug 5, 2026
Current price: IDR 2,060. This is the first update since 6 June. Two months, one MSCI decision, one full earnings release, one deep dive into valuation ratios, and a complete change in the picture. Here is everything that happened.

Chandra Asri Pacific (TPIA): One Day Up 12%, The Next Day Down 13% — Here’s What’s Really Going On

TPIA is a record-earning, fundamentally transformed company trading at a five-year low — and the next twenty days, specifically the MSCI review on June 23, will determine whether this is the buying opportunity of 2026 or the beginning of something much more serious for Indonesia's stock market.

Indonesia’s largest petrochemical company just reported the best quarter in its history. Its stock is near a five-year low. And the next three weeks could decide everything. If you’ve been watching PT Chandra Asri Pacific (TPIA) this week, you’ve seen one of the most dramatic two-day reversals on the Jakarta exchange in recent memory. On Tuesday, June 2, the stock surged 12% to…

At writing · TPIA Rp 1,615 Read more →
● 1 update — View →
Jun 2, 2026 · Long ·HIMSNASDAQ ·NASDAQ TELEHEALTH
Latest update · Jun 7, 2026
Verdict: The Direction Is Right. The Details Are Dangerously Incomplete.

The Case for Hims & Hers Health: Why the Market is Wrong About the GLP-1 Shakeout

Hims & Hers is an incredibly resilient, cash-rich digital health leader that the market has fundamentally mispriced at under 2.0x forward revenues due to a short-sighted overreaction to temporary GLP-1 compounding regulations.

Turning Regulatory Turbulence into an Asymmetric Buying Opportunity: The Case for Hims & Hers Health The world of growth investing rarely offers second chances. When a hyper-growth company experiences a sharp 60% drawdown from its market highs, the investing community often reacts with panic rather than analytical curiosity. This is exactly what is happening with Hims &…

At writing · HIMS USD 27.25 Read more →